Abstract
As clinical trials increasingly are conducted across the globe, pharmaceuticals, life sciences, and biotech sector companies face both opportunity and challenge especially in emerging markets. Everything from maintaining supply chain stability to accommodating data from a growing array of sources into what often are still siloed systems is at issue. India has emerged as one of the preferred destinations for the clinical trials of drugs by multinational pharmaceutical companies in recent years. The reasons for this include reasonably high standards of quality healthcare and healthcare professionals, use of the English language and the sheer size of target populations available in our country. Clinical trials are usually multi‐centric but trials in North America and Europe turn out to be time consuming and expensive. While clinical trials in the west are not totally free from compromised interest, mishaps and litigation, the medical research organizations (MRO) are licensed and highly regulated and people are sufficiently aware of the possible risks of such trials and also aware of their rights to healthcare. In India, the scenario is very different. A non‐uniform healthcare system, with varying standards in the government and private sectors, desperate poverty and lack of access to healthcare, illiteracy, lack of information and poor enforcement constitute a chaotic milieu which is a major challenge for a programme as critical as a clinical trial. Clinical research industry looks promising in India but motivating more and more doctors, hospital ,administrators and other life science professional towards a clinical research is require to achieve a sustain growth. Global standard quality sites with ample pool are one of the most attractive features global pharmaceutical and biotechnology, giants. Developing new clinical research site will certain open many more door for clinical research outsourcing in India.
